Trial Condition(s):
Venous Thromboembolism
Dose-confirmatory bridging study in total hip replacement
Bayer Identifier:
14397
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing elective total hip replacement (THR) and to confirm the extrapolability of global data to Japanese patients by comparing with data from overseas phase II study (ODIXa-OD.HIP - Study 11527).
Inclusion Criteria
- Male and female patients aged 20 years or above - Patients undergoing elective THR (the first replacement of the applicable hip joint) - Patients’ written informed consent to participation after receiving detailed verbal and written information on any study specific procedures in advance
Exclusion Criteria
- Planned, staged major orthopedic surgery within 3 months prior to elective THR or during this study - History of clinically significant active bleeding (e.g. intracranial bleeding, gastrointestinal bleeding*), or high bleeding risk *: within 3 months prior to elective THR for gastrointestinal bleeding - Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk - Severe impaired renal function (CLCR calculated by Cockcroft-Gault formula: <30 mL/min) - Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media) - Ongoing anticoagulant therapy (e.g. warfarin, heparins and Factor Xa inhibitors other than study medication) that cannot be stopped (in the opinion of the investigator/sub investigator) - Subjects for whom epidural catheters are expected to be left in for longer than 18 hours post-operatively - Planned intermittent pneumatic compression during treatment period
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | |
|---|---|---|
Locations Investigative Site Asahikawa, Japan, 078-8237 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hakodate, Japan, 040-8611 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Koriyama, Japan, 963-8501 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tsukuba, Japan, 305-0854 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Matsudo, Japan, 271-8511 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Narashino, Japan, 275-8580 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nerima-ku, Japan, 177-8521 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Yokohama, Japan, 236-0004 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kamakura, Japan, 247-0061 | Status Completed | Contact Us: E-mail: clinical-trials-cont[email protected] Phone: Not Available |
Locations Investigative Site Iida, Japan, 395-8505 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nagoya, Japan, 455-8530 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kyoto, Japan, 602-8026 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osaka, Japan, 530-0012 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osaka, Japan, 553-0003 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osaka, Japan, 558-8558 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Takatsuki, Japan, 569-1192 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Suita, Japan, 564-0082 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hirakata, Japan, 573-1191 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hirakata, Japan, 573-8511 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sakai, Japan, 599-8271 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osakasayama, Japan, 589-8511 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kishiwada, Japan, 596-8522 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kishiwada, Japan, 596-8501 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Izumisano, Japan, 598-8577 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Izumi, Japan, 594-0071 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kobe, Japan, 657-0068 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nishinomiya, Japan, 663-8501 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kakogawa, Japan, 675-8545 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kurashiki, Japan, 710-8522 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kurashiki, Japan, 710-8522 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Fukuoka, Japan, 813-0017 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Fukuoka, Japan, 814-8525 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Saga, Japan, 849-8501 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sasebo, Japan, 857-0135 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sasebo, Japan, 857-8575 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kumamoto, Japan, 862-8505 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kagoshima, Japan, 890-0014 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tomigusuku, Japan, 901-0243 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Setagaya, Japan, 158-0095 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Toyama, Japan, 930-8550 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Matsuyama, Japan, 790-8524 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sapporo, Japan, 060-8648 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Randomized, double-blind, parallel-group, active-controlled, dose-confirmatory bridging study of rivaroxaban (BAY59-7939) 5 to 10 mg once-daily regimen with a reference drug of enoxaparin in the prevention of venous thromboembolism in patients undergoing elective total hip replacement
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Prevention
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Parallel Assignment
Trial Arms:
4
Primary Outcome
- A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causesTimeframe: Up to Day 9 (±2 days)
- Treatment-emergent bleeding (major, non-major clinically relevant, other non-major)Timeframe: Up to Day 8 (±2 days)
Secondary Outcome
- Deep vein thrombosis (total, proximal, distal)Timeframe: up to Day 9 (±2 days)
- Symptomatic venous thromboembolismTimeframe: up to Day 9 (±2 days)
- Major venous thromboembolism (proximal deep vein thrombosis, pulmonary embolism or venous thromboembolism-related death)Timeframe: up to Day 9 (±2 days)
- Symptomatic venous thromboembolismTimeframe: up to Day 36 (±4 days)
- Symptomatic venous thromboembolismTimeframe: within 30 days after stop of treatment with study drug.
- Treatment-emergent bleeding (major, non-major clinically relevant, other non-major)Timeframe: from the first intake of study medication to no later than 2 days after the last intake of study drug
Additional Information
Copyright © Bayer
Powered by
